Who was studied, and how
Five numbers in the abstract
Where each one falls
Where it lands on the map
people with dyslipidemia, in this paper
The trial randomly assignedassigned by chance
ezetimibe 10 mg and simvastatin 40 mg, coadministered
placebo
Reported lower plasma concentrations of cholesterol, no range given−43.0
Reported lower plasma concentrations of LDL-C, no range given−53.6
Reported lower plasma concentrations of triglycerides, no range given−44.0
randomisedthe abstract, start to end
… plasma concentrations of cholesterol (-43.0%), LDL-C (-53.6%), and triglycerides (-44.0%).
… size (PS) was significantly decreased (-48.9%) following combination therapy mainly through a significant reduction in TRL apoB-48 production rate (PR) (-38.0%).
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Plasma concentrations of cholesterolezetimibe 10 mg and simvastatin 40 mg, coadministered vs placebo
−43.0
Plasma concentrations of LDL-Cezetimibe 10 mg and simvastatin 40 mg, coadministered vs placebo
−53.6
Plasma concentrations of triglyceridesezetimibe 10 mg and simvastatin 40 mg, coadministered vs placebo
−44.0
Triglyceride-rich lipoproteins (TRL) apoB-48 pool size (PS)ezetimibe 10 mg and simvastatin 40 mg, coadministered vs placebo
−48.9
TRL apoB-48 production rate (PR)ezetimibe 10 mg and simvastatin 40 mg, coadministered vs placebo
−38.0
StatinsOther lipid agentsLipidsPharmacokinetics & dosing
1 / 4